CARA THERAPEUTICS, INC. (NASDAQ:CARA) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07.
|
Submission of Matters to a Vote of Security Holders. |
On June21, 2017, Cara Therapeutics, Inc. (the Company) held its
Annual Meeting of Stockholders (Annual Meeting). At the Annual
Meeting, the Companys stockholders voted on the two proposals set
forth below. A more detailed description of each proposal is set
forth in the Companys Proxy Statement filed with the Securities
and Exchange Commission on May10, 2017.
Proposal 1 Election of Directors
Dr.Derek Chalmers and Mr.Martin Vogelbaum were elected to serve
as directors of the Companys Board of Directors until the 2020
Annual Meeting of Stockholders and until their successors are
duly elected or until their earlier resignation or removal, by
the following votes:
|
|
|
|
|
|||
|
|
9,723,635 | 1,280,647 | 13,758,180 | |||
|
|
9,171,424 | 1,832,858 | 13,758,180 |
Proposal 2 Ratification of the Selection of Independent
Registered Public Accounting Firm
The stockholders ratified the selection of Ernst Young LLP as the
Companys independent registered public accounting firm for the
year ending December31, 2017, by the following votes:
|
|
|
|
||
|
|
|
|
About CARA THERAPEUTICS, INC. (NASDAQ:CARA)
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body’s peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company’s I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company’s CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.